A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with type 2 diabetes lower blood sugar.
Recruiting now. Registry record last updated April 20, 2026.
- Who can join
- Adults 30 to 70, have type 2 diabetes, BMI 19+.
- What you take
- Tirzepatide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
- How long it lasts
- The full study runs about 3 years.
- What you get
- Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.
What this study is for
Primary condition: Diabetes Mellitus, Type 2. Also studied in: Diabetes, Type 2 Diabetes, Pre Diabetes.
Full scientific study title: Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide.
Who can join
Adults 30 to 70, have type 2 diabetes, BMI 19+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.
Full medical eligibility (for you and your doctor)verbatim from the registry
This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.
Key inclusion criteria
- Age: 30 to 70 years old.
- Diagnosis of Type 2 Diabetes (T2D): Based on a previous diagnosis or confirmed by laboratory testing at screening (A1c \> 5.7% or fasting glucose \> 100 mg/dL).
- HbA1c Range: Between 5.7% and 8%, with a stable medication or lifestyle regimen for at least 3 months.
- BMI: Between 19 and 24.9 kg/m².
- Diabetes Medications: All diabetes medications are allowed, except insulin and pioglitazone. GLP-1 receptor agonists are permitted if the dose has been stable for 3 months.
Key exclusion criteria
- Pregnancy or Lactation: Women who are pregnant, planning to become pregnant, or breastfeeding are excluded due to potential risks to the fetus or infant.
- Prior Use of Pioglitazone: Participants who have previously used pioglitazone are excluded to avoid confounding effects of prior drug exposure.
- Unstable Body Weight: Individuals with a body weight change of more than 2 kg in the last 3 months are excluded to ensure stable metabolic conditions.
- Liver or Kidney Disease: Participants with significant liver disease (ALT \> 3x upper limit of normal) or renal disease (creatinine \> 1.5 mg/dL) are excluded due to potential safety risks.
- Congestive Heart Failure or Fluid Overload History: These conditions are exclusionary due to the risk of fluid retention with pioglitazone.
Where this trial is enrolling
This trial has 2 sites across 1 state. Contact a site coordinator directly to start screening.
California2 sites
- Stanford UniversityPalo Alto, California
- Stanford University, Clinical and Translational Research Unit (CTRU)Stanford, California
Timeline
Started enrolling: January 13, 2025. Expected completion: December 15, 2027. Last updated on ClinicalTrials.gov: April 20, 2026.
Official source
Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:
Other GLP-1 clinical trials
Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.
